Résumé
Objective@#To evaluate effect of Tanreqing injection combined conventional western medicine therapy on acute exacerbation of chronic obstructive pulmonary disease (AECOPD) of Phlegm heat obstructing Lung.@*Methods@#A total of 112 patients with AECOPD were randomly divided into two groups with digital table method from February 2015 to February 2018, 56 cases in each group. The control group was treated byconventional western medicine therapy, and treatment group was treated by Tanreqing injection based on control group. Both groups' treatment lasted for 2 weeks. The modified version of British Medical Reseach Council respiratory questionnaire (mMRC) was used for severity evaluation in breath difficulty. The COPD assessment test (CAT) was used for the assessment of symptoms, activity ability, psychological, social impact and sleep. The FEV1% and FEV1/FVC were recorded. The SaO2, PaO2 and PaCO2 were recorded. The phlegm heat obstructing lung symptom scores were detected. The adverse reactions were recorded.@*Results@#The total effective rate of treatment group was 94.4% (51/54), and the control group was 77.3% (41/53). There was statistically significant difference between two groups (χ2=5.138, P=0.023). After treatment, the mMRC and CAT scores in the treatment group were significantly lower than those in the control group (t value were 17.233, 17.111, respectively, all Ps<0.01); the cough, wheezing, shortness of breath, fever, dry mouth, constipation scores were significantly lower than the control group (t value were 27.717, 29.387, 27.227, 30.268, 28.430, 29.738, respectively, all Ps<0.01). After treatment, the FEV1% (52.34% ± 5.79% vs. 46.98% ± 5.72%, t=4.817), FEV1/FVC (61.36 ± 6.52 vs. 56.93 ± 5.94, t=3.675) in the treatment group were significantly higher than the control group (P<0.01); SaO2 (90.11% ± 9.53% vs. 83.56% ± 8.84%, t=3.684); the PaO2 (91.22 ± 9.79 mmHg vs. 85.18 ± 8.80 mmHg, t=3.354) significantly higher than the control group (P<0.01), and PaCO2 (44.75 ± 4.94 mmHg vs. 51.05 ± 5.46 mmHg, t=6.261) significantly lower than the control group (P<0.01). The incidence of adverse reactions in the treatment group was 11.1% (6/54), and the control group was 7.5% (4/53). There was no statistically significant difference between two groups (χ2=0.091, P=0.763).@*Conclusions@#Tanreiqing injection combined with conventional western medicine therapy can take effectsimprove levels of SaO2 and PaO2, reduce PaCO2 level of the AECOPD patients.
Résumé
Objective@#To explore the optimal concentration of Tanreqing injection for acute upper respiratory tract infections.@*Methods@#A retrospective analysis of 531 children with acute upper respiratory tract infection treated with Tanreqing injection was conducted. These children were divided into different groups according to concentration of Tanreqing injection (i.e., the relationship between liquid and solvent, or the dilution ratio of solvent to liquid). Assume that X was the dilution ratio of solvent to liquid and the group was divided by an additional increment of 2.5 dilution units. All the children were divided into six groups as follows, groups of A (1:10≤X<1:12.5), B (1:12.5≤X<1:15), C (1:15≤X<1:17.5), D (1:17.5≤X<1:20), E (1:20≤X<1:22.5) and F (1:22.5≤X<1:25). The clinical effective rate and incidence of adverse reactions in each group were used as clinical indicators related to concentration of Tanreqing injection. Origin 8 was used to establish the relationship between the two indicators and the median of the concentration, and to seek a net benefit index that can combine the two indicators together. Finally, the relationship between the net benefit indicator and the median of the concentration were established, and the optimal concentration was found by judging and picking up the maximum of the net benefit indicator.@*Results@#The relationship between the clinical effective rate and the concentration median were: Y=-0.3+31.58X-203.33X2 (R2=0.988 46), and relationship between the incidence of adverse reactions and the concentration median were: Y=-0.27+10.24X-67.85X2 (R2=0.982 28), and relationship between the net benefit indicator and the concentration median were: ΔY=-0.03+21.34X-135.48X2. The peak value of the net benefit indicator was 0.81, and the corresponding median of the concentration was 0.078 8, and the optimal dilution ratio of liquid to solvent was 1:11.6-1:14.1.@*Conclusions@#This article explored the optimum concentration range of Tanreqing injection and gave tips for clinical safety and effective drug use.
Résumé
Objective To explore the optimal concentration of Tanreqing injection for acute upper respiratory tract infections. Methods A retrospective analysis of 531 children with acute upper respiratory tract infection treated with Tanreqing injection was conducted. These children were divided into different groups according to concentration of Tanreqing injection (i.e., the relationship between liquid and solvent, or the dilution ratio of solvent to liquid). Assume that X was the dilution ratio of solvent to liquid and the group was divided by an additional increment of 2.5 dilution units. All the children were divided into six groups as follows, groups of A (1:10≤X<1:12.5), B (1:12.5≤X<1:15), C (1:15≤X<1:17.5), D (1:17.5≤X<1:20), E (1:20≤X<1:22.5) and F (1:22.5≤X<1:25). The clinical effective rate and incidence of adverse reactions in each group were used as clinical indicators related to concentration of Tanreqing injection. Origin 8 was used to establish the relationship between the two indicators and the median of the concentration, and to seek a net benefit index that can combine the two indicators together. Finally, the relationship between the net benefit indicator and the median of the concentration were established, and the optimal concentration was found by judging and picking up the maximum of the net benefit indicator. Results The relationship between the clinical effective rate and the concentration median were: Y=-0.3+31.58X-203.33X2 (R2=0.988 46), and relationship between the incidence of adverse reactions and the concentration median were: Y=-0.27+10.24X-67.85X2 (R2=0.982 28), and relationship between the net benefit indicator and the concentration median were: ΔY=-0.03+21.34X-135.48X2. The peak value of the net benefit indicator was 0.81, and the corresponding median of the concentration was 0.078 8, and the optimal dilution ratio of liquid to solvent was 1:11.6-1:14.1. Conclusions This article explored the optimum concentration range of Tanreqing injection and gave tips for clinical safety and effective drug use.